Skip to main content

Boston biotech Verve tests ‘CRISPR 2.0′ in a patient for the first time

Submitted by mharada on July 14, 2022 - 02:29 PM

US biotechnology company Verve Therapeutics has dosed the first patient with its base editing technology in a clinical trial in New Zealand. The base editor introduces a mutation in the PCSK9 gene in the liver to lower the levels of LDL cholesterol.

Content Source:

The Boston Globe

Content Author:

Ryan Cross

Tags: